Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs November 23, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight November 22, 2021 • 4:05 PM EST
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers November 15, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021 November 9, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021 November 8, 2021 • 4:05 PM EST
Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights November 8, 2021 • 7:00 AM EST
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland October 15, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference October 7, 2021 • 7:00 AM EDT
